Robert Chess Sells 3,600 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess sold 3,600 shares of the stock in a transaction on Monday, November 11th. The shares were sold at an average price of $47.26, for a total value of $170,136.00. Following the sale, the director now owns 21,641 shares in the company, valued at approximately $1,022,753.66. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Twist Bioscience Stock Down 6.1 %

NASDAQ:TWST traded down $2.77 during trading hours on Wednesday, reaching $42.49. 962,106 shares of the stock were exchanged, compared to its average volume of 941,048. The firm has a 50 day simple moving average of $43.92 and a 200-day simple moving average of $45.93. Twist Bioscience Co. has a 52 week low of $18.59 and a 52 week high of $60.90. The stock has a market capitalization of $2.49 billion, a P/E ratio of -11.12 and a beta of 1.78.

Wall Street Analyst Weigh In

TWST has been the topic of a number of analyst reports. Evercore ISI increased their target price on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Barclays decreased their price objective on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. Leerink Partners raised their price objective on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a report on Thursday, October 17th. JPMorgan Chase & Co. lifted their target price on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a report on Monday, August 5th. Finally, Robert W. Baird lifted their target price on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a report on Monday, August 5th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $51.22.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Thrivent Financial for Lutherans bought a new stake in shares of Twist Bioscience in the 3rd quarter worth approximately $43,992,000. Point72 Asset Management L.P. lifted its holdings in shares of Twist Bioscience by 1,021.8% in the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock worth $33,168,000 after purchasing an additional 613,057 shares during the last quarter. Fred Alger Management LLC lifted its holdings in shares of Twist Bioscience by 720.7% in the 2nd quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock worth $32,272,000 after purchasing an additional 575,080 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Twist Bioscience by 4,133.1% in the 2nd quarter. Victory Capital Management Inc. now owns 308,171 shares of the company’s stock worth $15,187,000 after purchasing an additional 300,891 shares during the last quarter. Finally, Farallon Capital Management LLC bought a new stake in shares of Twist Bioscience in the 2nd quarter worth approximately $9,462,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.